FDA's Advisory Meetings（８月31日）
公開日時 2009/09/02 04:00
| Recent And Upcoming FDA Advisory Meetings |
| Topic |
Advisory Committee |
Date |
| GE Healthcare's radiopharmaceutical DaTSCAN (ioflupane I 123 injection) for a special type of brain imaging in patients with movement disorders |
Peripheral and Central Nervous System Drugs |
Aug. 11 |
| Amgen's Prolia (denosumab) for treatment and prevention of osteoporosis in postmenopausal women, and for treatment and prevention of bone loss in patients undergoing hormone ablation for prostate or breast cancer |
Reproductive Health Drugs |
Aug. 13 |
| Genzyme's Clolar (clofarabine) injection for added indication of acute myeloid leukemia in patients over age 60 with at least one unfavorable prognostic factor; Vion's Onrigin (laromustine) injection for remission induction in patients over 60 with de novo poor-risk AML |
Oncologic Drugs |
Sept. 1 |
| Gloucester's Istodax (romidepsin) for cutaneous T-cell lymphoma, including relief of pruritus; Allos Therapeutics' Folotyn (pralatrexate) for relapsed or refractory peripheral T-cell lymphoma |
Oncologic Drugs |
Sept. 2 |
| GlaxoSmithKline's Human Papillomavirus vaccine for use in females, and Merck's HPV vaccine Gardasil for use in males |
Vaccines and Related Biological Products |
Sept. 9 |
| Auxilium Pharmaceuticals' BLA for clostridial collagenase for advanced Dupuytren's disease |
Arthritis Drugs |
Sept. 16 |
| Neuromed's Exalgo (modified-release hydromorphone) for moderate to severe pain in opioid-tolerant patients |
Anesthetic Life Support Drugs and Drug Safety and Risk Management |
Sept. 23 |
| Schering Plough's PegIntron (peginterferon alfa-2b) as an adjuvant to surgery for metastatic melanoma, and GlaxoSmithKline's Amala (pazopanib) for advanced renal cell carcinoma |
Oncologic Drugs |
Oct. 5 |
| ApoPharma's Ferriprox (deferiprone) as an iron chelating agent to treat iron overload or build-up in patients with transfusion-dependent thalassemia or other transfusion-dependent anemias |
Oncologic Drugs |
Oct. 6 |
| Pfizer's Selzentry (maraviroc) for supplemental indication to treat antiretroviral-naïve patients with chemokine (c-c motif) receptor 5 (CCR5) tropic human immunodeficiency virus |
Antiviral Drugs |
Oct. 8 |
| Acorda Therapeutics' Amaya (fampidine-SR) to improve walking ability in multiple sclerosis patients |
Peripheral and Central Nervous System Drugs |
Oct. 14 |
（The Pink Sheet ８月31日号より） FDAと米国製薬企業の情報満載 “The Pink Sheet”はこちらから